BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 18, 2025
Home » BioWorld Stock Report For Public Biotechnology Companies

BioWorld Stock Report For Public Biotechnology Companies

Feb. 19, 2007


Article reprints

To read more on related topics, click on one of the words below.

BioWorld MedTech
    • Related Articles

      BioWorld Stock Report For Public Biotechnology Companies

      BioWorld Stock Report For Public Biotechnology Companies

      BioWorld Stock Report For Public Biotechnology Companies

    Popular Stories

    • Today's news in brief

      BioWorld
      BioWorld briefs for Dec. 18, 2025.
    • Today's news in brief

      BioWorld MedTech
      BioWorld MedTech briefs for Dec. 18, 2025.
    • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

      HIV research is close to a cure but far from ending the pandemic

      BioWorld
      Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
    • GLP-1 capsule

      Maintenance, man: Lilly’s phase III weight trial hits goals

      BioWorld
      Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
    • Insilico CEO Alex Zhavoronkov and the automated lab’s humanoid that runs all preclinical tests in the Hong Kong lab.

      AI drug developer Insilico to raise $292 million in Hong Kong IPO

      BioWorld
      Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...
    • BioWorld
      • Today's news
      • Analysis and data insight
      • Clinical
      • Data Snapshots
      • Deals and M&A
      • Financings
      • Newco news
      • Opinion
      • Regulatory
      • Science
    • BioWorld MedTech
      • Today's news
      • Clinical
      • Data Snapshots
      • Deals and M&A
      • Financings
      • Newco news
      • Opinion
      • Regulatory
      • Science
    • BioWorld Asia
      • Today's news
      • Analysis and data insight
      • Australia
      • China
      • Clinical
      • Deals and M&A
      • Financings
      • Newco news
      • Regulatory
      • Science
    • BioWorld Science
      • Today's news
      • Biomarkers
      • Cancer
      • Conferences
      • Endocrine/Metabolic
      • Immune
      • Infection
      • Neurology/Psychiatric
      • NME Digest
      • Patents
    • More
      • About
      • Advertise with BioWorld
      • Archives
      • Article reprints and permissions
      • Contact us
      • Cookie policy
      • Copyright notice
      • Data methodology
      • Infographics: Dynamic digital data analysis
      • Index insights
      • Podcasts
      • Privacy policy
      • Share your news with BioWorld
      • Staff
      • Terms of use
      • Topic alerts
    Follow Us

    Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing